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Background/aim: To evaluate the pre and post-treatment heart rate and oxygen (O2) saturation values measured before, during and
after 6MWT in children who received PAH-specific treatment and to determine the effect of these variables on prognosis.
Materials and methods: This retrospective study included 29 patients who were diagnosed as PAH and treated. The transcutaneous O2
saturation and heart rate levels were recorded before the test: baseline (Sat0, HR0), at the end of the test: exercise (Sat1, HR1) and 5 min
after the test: recovery (Sat2, HR2). The increase in heart rate was defined as HR1-HR0 and the decrease in saturation as Sat0-Sat1. The
results obtained before and after the PAH-specific treatment were analyzed and their effect on survival was assessed.
Results: Fifteen of 29 patients were female (51.7%). The mean age was 127.2 ± 44.8 months and the median follow-up time was 60
(12–156) months. Only pre-treatment HR1 was found associated with survival. The mean HR1 value of survivors was 122.8 ± 18.4 and
that of deceased 94.3 ± 19.1 (p = 0.03). Post-treatment 6MWT was associated with survival. It was 453.3 ± 96.5 m for survivors and 250
± 135.2 m for deceased (p = 0.02).
Conclusion: Post-treatment 6MWT, FC and proBNP had prognostic value in pediatric patients with PAH. The decrease in saturation
and increase in heart rate were not found to have a prognostic value. Pre-treatment HR1 was associated with survival. Identification
of these prognostic factors at the beginning and throughout the treatment may be a guide for detecting the severity of the disease and
follow-up.
Key words: 6-minute walk test, pulmonary arterial hypertension, survival, heart rate

1. Introduction
Until recently, pulmonary hypertension has been widely
considered within the context of adult disease. Because of this
view, the role of the pediatric disease has been limited and
complicated with many unanswered questions throughout
the long history of pulmonary hypertension. Finally, the
guidelines of the European Society of Cardiology (ESC)/
European Respiratory Society (ERS) have underlined the
necessity of specific schedules for the diagnosis, follow up and
treatment of affected children [1]. After these guidelines of
ESC/ERS, two pediatric-specific guidelines were published in
a little while [2,3]. However, there are still different opinions
about the value of some prognostic factors in both pediatric
guidelines [4]. The 6-minute walk test (6MWT) is one of them.
6MWT is effective in predicting survival and useful as
a prognostic factor in adults [5,6]. However, the prognostic
value of 6MWT is controversial in children due to the

difficulty of its feasibility and lack of sufficient data and
studies have varying results [7–12]. Although the degree of
desaturation and heart rate variations during 6MWT have
been shown to be an additional predictor factor in adults
with pulmonary arterial hypertension (PAH) [13–15], few
studies are investigating this in children [16].
In this study, our objective was to evaluate the pre
and post-treatment heart rate and oxygen (O2) saturation
values measured before, during and after 6MWT in
children who received PAH-specific treatment and to
determine the effect of these variables on prognosis.
2. Materials and methods
This retrospective study included 29 patients who were
eligible to undergo a 6MWT out of 41 patients diagnosed
as PAH and treated at the Pediatric Cardiology Clinic of
University Hospital.
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Inclusion criteria were; ≥ 7 and < 18 years of age,
diagnosis of PAH either secondary to congenital heart
disease or idiopathic, and eligibility to undergo 6MWT.
Exclusion criteria were; children with a chromosomal
abnormality and genetic disorders, inability to perform
6MWT due to physical or mental retardation.
The criteria for PAH diagnosis were; mean pulmonary
arterial pressure (mPAP) ≥ 25 mmHg during a heart
catheterization, pulmonary capillary wedge pressure
(PCWP) ≤ 15 mmHg, and pulmonary vascular resistance
index (PVRI) ≥ 3 Wu.m2 [17]. The test was conducted
according to the guidelines reported by the American
Thoracic Society (ATS) [18]. The patients’ demographic
characteristics, etiologies of PAH, WHO functional classes
(FC), and PAH-specific treatment modalities were recorded.
ProBNP (brain natriuretic peptide) levels were measured.
The patients were assessed by their PAH follow-up protocols
during their quarterly follow-up and 6MWT was performed
in each follow-up visit. The transcutaneous O2 saturation
and heart rate levels were recorded before the test: baseline
(Sat0, HR0), at the end of the test: exercise (Sat1, HR1) and
5 min after the test: recovery (Sat2, HR2). Heart rate and
transcutaneous O2 saturation were measured with a handheld pulse oximeter (PC-60B, China) placed on the patient’s
right-hand index finger.
The increase in heart rate was defined as HR1-HR0 and
the decrease in saturation as Sat0-Sat1. The results obtained
before and after the PAH-specific treatment were analyzed
and their effect on survival was assessed.
2.1. Statistical analysis
All statistical analyses were performed using the SPSS
(Statistical Package for Social Sciences) v: 15.0 (SPSS Inc,
Chicago, IL). Continuous data were presented as means with
standard deviation or medians with minimum and maximum
values. Categorical data were presented as frequencies and
percentages. Continuous variables were tested for normal
distribution using the Kolmogorov–Smirnov test. Two
dependent groups were compared using the paired sample
t-test for normal distributions and the Wilcoxon test for
nonnormal distributions. Correlation coefficients (r) were
calculated using the Pearson correlation test or Spearman’s
rank test, depending on the normality of the p-value.
Kaplan–Meier curves with log-rank tests were plotted for the
patients who scored below and above the median 6MWT.
Univariate survival analysis was performed using the Coxregression test. A two-sided p-value < 0.05 was considered
statistically significant for all analyses. An a priori power
analysis was conducted in G*Power Software (v: 3.1.9.5;
Franz Faul, Universität Kiel, Germany). The sample size
calculation was based on the mean 6MWT values derived
from previous research and an alpha significance level set
at 0.05, to achieve 80% statistical power approximately 28
individuals would have to be recruited [19].
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3. Results
Fifteen of 29 patients were female (51.7%). The mean
age was 127.2 ± 44.8 months and the median follow-up
time was 60 (12–156) months. Two patients (6.9%) were
diagnosed with idiopathic PAH and 27 patients (93.1%)
with secondary PAH. The ventricular septal defect was
the most common (38%) congenital heart disease among
the etiologies of secondary PAH. All patients underwent
cardiac catheterization. The comparison of patients’
clinical characteristics between before and after treatment
were shown in Table 1.
3.1. Heart rate and saturation assessment
The post-treatment HR1 was significantly higher than pretreatment (132.3 ± 22.7, 118.9 ± 20.4, p = 0.017), but there
was no significant difference in HR0 and HR2 (Table 1).
The pre-treatment Sat1 and Sat2 were significantly higher
than post-treatment (p = 0.003, p = 0.017) (Table 1).
3.2. Comprehensive 6MWT evaluation and correlations
The pre- and post-treatment 6MWT had a significant
negative correlation with both FC and proBNP (p = 0.004,
p < 0.001; p = 0.046, and p = 0.003 respectively) (Table 2).
Pre-treatment 6MWT had a significant positive
correlation with Sat0, 1, 2 (p = 0.015, p = 0.012, p < 0.001)
while post-treatment 6MWT had with only Sat0 and Sat2
(p = 0.035, p = 0.004).
Pre-treatment 6MWT was negatively correlated with
HR0 and HR2 (p = 0.046, p = 0.029) and post-treatment
6MWT with only HR0 (p = 0.037).
Pre-treatment FC had a significant negative correlation
with only Sat2 and post-treatment FC with all Sat0, 1, and
2. While desaturation had no correlation with proBNP, it
had a significant positive correlation with post-treatment
FC (p = 0.04, r = 0.0378).
There was no correlation between Sat0, 1, 2, and
proBNP before or after the treatment.
Heart rate increases, HR0, 1, 2 were not correlated with
pre- and post-treatment FC or proBNP.
There was no significant correlation between pretreatment FC and proBNP, but a statistically significant
positive correlation was found after the treatment (p =
0.003).
3.3. FC III-IV versus FC I-II
While 16.7% of the 6 patients who were FC I -II at
the initial assessment regressed to FC III-IV after the
treatment, 65.2% of the 23 patients who were FC III-IV at
baseline improved to FC I-II and 34.8% of them remained
as FC III-IV (p < 0.001). In the final assessment, the
6MWT distance and proBNP of the patients who were
FC III-IV were significantly higher than those whom FC
I-II (p = 0.003; p = 0.020, respectively) (Table 3). Only the
post-treatment Sat2 value was significantly lower in those
who were FC III-IV (p = 0.033) (Table 3). Pre- and post-
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Table 1. Comparison of variables before and after treatment.
Variables

Before treatment

After treatment

P-value

proBNP (pg/mL)*

218 (20–9000)

186 (10–7958)

0.112

6MWT (m)*

390 (120–624)

441 (120–603)

0.026

Mean PAP (mmHg)

53 (15–110)

71.5 (34–137)

0.003

0

87.3 ± 12.3

86.6 ± 9.1

0.470

1

76.2 ± 21.6

65.0 ± 26.7

0.003

2

81.8 ± 16.6

71.7 ± 21.3

0.017

0

96.5 ± 15.9

95.2 ± 13.7

0.810

1

118.9 ± 20.4

132.3 ± 22.7

0.017

2

106.1 ± 17.4

114.5 ± 21.4

0.260

*

Saturation (%) +

HR (beat/min)

+

I

13.8

II

20.7

55.2

III

62.1

24.1

IV

17.2

6.9

Monotherapy (n)

11

9

Combined therapy (n)

18

17

FC (%)

*Data were presented as median (min-max), +Data were presented as mean ± standard deviation (SD). proBNP: brain natriuretic
peptide, m: meter, 6MWT: 6-minute walk test, PAP: pulmonary arterial pressure, HR: heart rate, FC: functional class.
Table 2. Correlations between variables before and after treatment.
Before treatment
Variables

6MWT (m)

proBNP (pg/mL)
FC
0
Saturation (%)

1
2
0

HR (beat/min)

1
2

proBNP
(pg/mL)

Corr. coef.

–0.373

P-value

0.046

Corr. coef.

–0.520

0.287

P-value

0.004

0.131

Corr. coef.

0.448

–0.150

P-value

0.015

0.437

Corr. coef.

0.459

P-value

0.012

Corr. coef.
P-value

1

After treatment
FC

6MWT (m)

0.287

–0.526

0.131

0.003

proBNP (pg/mL) FC
1

0.527
0.003

–0.672

0.527

<0.001

0.003

–0.338

0.400

–0.101

–0.507

0.073

0.035

0.609

0.006

–0.016

–0.312

0.320

–0.084

–0.443

0.936

0.100

0.096

0.669

0.018

0.654

–0.195

–0.490

0.535

–0.170

–0.546

<0.001

0.351

0.013

0.004

0.395

0.003

Corr. coef.

–0.374

–0.023

0.095

–0.436

0.191

0.056

P-value

0.046

0.906

0.625

0.020

0.330

0.777

Corr. coef.

–0.131

0.060

0.012

0.089

–0.105

–0.113

P-value

0.497

0.759

0.951

0.654

0.596

0.567

Corr. coef.

–0.438

0.054

0.118

–0.190

0.018

0.092

P-value

0.029

0.798

0.576

0.342

0.929

0.648

1

1

Corr. coef: correlation coefficient, FC: functional class, proBNP: brain natriuretic peptide, SAT0: baseline O2 saturation before the test,
SAT1: O2 saturation at the end of the test, SAT2: O2 saturation 5 min after the test, HR0: baseline heart rate before the test, HR1: heart
rate at the end of the test, HR2: heart rate 5 min after the test.
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Table 3. Comparison of variables between FC III-IV and FC I-II before and after treatment.
Before treatment

Variables

FC I - II (n: 6)

FC III - IV (n: 23)

P-value FC I - II (n: 20)

FC III - IV (n: 9)

P-value

proBNP
(pg/mL)

87.5

6MWT
(m)

453.5 (304.0 - –624.0) 377.0 (120.0 - 564.0)

0.085

486.0 (300.0 603.0) 345.0

(120.0 - 500.0)

0.003

0

97.0

(61.0

- 99.0)

90.0

(59.0

- 99.0)

0.099

93.0

(70.0

99.0)

83.0

(69.0

- 97.0)

0.052

Saturation 1
(%)
2

93.5

(48.0

- 97.0)

83.0

(25.0

- 98.0)

0.215

83.0

(16.0

98.0)

48.0

(17.0

- 97.0)

0.061

96.0

(52.0

- 99.0)

86.0

(54.0

- 98.0)

0.056

94.0

(34.0

99.0)

53.5

(52.0

- 78.0)

0.033

Decrease 3.0

(1.0

- 18.0)

7.0

(-3.0

- 48.0)

0.318

12.0

(-4.0

64.0)

27.0

(0.0

- 62.0)

0.140

0

(65.0

- 128.0)

95.0

(79.0

- 123.0)

0.957

97.0

(57.0

120.0) 95.0

(80.0

- 114.0)

0.999

124.0 (100.0 - 160.0)

116.0 (73.0

- 153.0)

0.319

141.0 (103.0 185.0) 128.0

(100.0 - 160.0)

0.459

108.0 (83.0

104.0 (80.0

- 137.0)

0.799

113.0 (71.0

164.0) 109.0

(80.0

- 142.0)

0.894

0.027

40.0

83.0)

(10.0

- 67.0)

0.313

1
HR
(beat/min) 2

98.0

Increase 43.0

(20.0–

1423.0) 282.0 (51.3

- 134.0)

(-13.0 - 47.0)

19.0

- 9000.0) 0.027

(-19.0 - 48.0)

98.3

(23.9

(10.0

823.0) 1337.0 (10.0

23.0

- 7958.0) 0.020

Data were presented as median (min-max), FC: functional class, proBNP: brain natriuretic peptide, SAT0: baseline O2 saturation before
the test, SAT1: O2 saturation at the end of the test, SAT2: O2 saturation 5 min after the test, HR0: baseline heart rate before the test, HR1:
heart rate at the end of the test, HR2: heart rate 5 min after the test.

treatment HR0, 1, and 2 did not differ between FC III-IV
and FC I-II. Pre-treatment heart rate increase was found
significantly higher in those who were FC I-II (p = 0.027)
(Table 3).
3.4. Survival factors
During follow-up, 3 patients in FC III-IV have died.
The first patient who was followed up for patent ductus
arteriosus-related PAH died due to a serious lung infection.
The second and third patient diagnosed as residual and
idiopathic PAH were lost from heart failure. Only pretreatment HR1 was found associated with survival. The
mean HR1 value of survivors was 122.8 ± 18.4 and that of
deceased 94.3 ± 19.1 (p = 0.03) (Table 4).
Post-treatment 6MWT was associated with survival. It
was 453.3 ± 96.5 m for survivors and 250 ± 135.2 m for
the deceased (p = 0.02) (Table 4). A ROC analysis revealed
that the cut-off value for 6MWT was 315 m with 66.7%
sensitivity and 92.3% specificity (Figure 1). The survival
time was 53 ± 28.9 months for whom 6MWT < 315 m and
64.9 ± 41.1 months for whom 6MWT > 315 m (p = 0.01)
(Figure 2). A high level of post-treatment proBNP affected
survival negatively (p = 0.004). Similarly, post-treatment
FC being III-IV had a 9-fold negative effect on survival
(Table 4).
4. Discussion
Our study showed that pre- and post-treatment 6MWT in
pediatric patients with pulmonary arterial hypertension
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was negatively correlated with FC and proBNP and all
of these three parameters were associated with posttreatment survival. A high pre-treatment heart rate (HR1)
as measured at the end of the test was found to have a
positive impact on survival. The saturation decrease and
heart rate increase during the test seemed to have no
prognostic effect on survival.
Studies investigating the prognostic value of 6MWT
in pediatric patients with PAH have conflicting results
[7–12]. Ivy et al. have stated that unlike in adults,
6MWT should not be used in children with PAH for risk
assessment [7]. Studies are having similar results in the
literature [20,21]. Whereas, Lammers et al. reviewed the
data of 47 children with PAH with a mean age of 11.4 years
and reported that 6MWT as a predictor factor for death
or need for transplantation [10]. Our study also revealed
that there was a statistically significant increase in posttreatment 6MWT distance and post-treatment test was
associated with survival. Additionally, the fact that 6MWT
had a significant negative correlation with FC and proBNP
as two important predictor factors before and after the
treatment, showed that this test could be used to evaluate
the prognosis and severity of the disease. The cut-off point
for the test was found to be 315 m in our study and those
whose 6MWT distance > 315 m were shown to have better
survival. The test can also be used to evaluate the quality
of life and the effort capacity of patients irrespective of
survival.
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Table 4. Parameters associated with patient survival.

N

Death
n (%)

Univariate analysis

I-II

6

-

1

III-IV

23

3 (13.0)

HR

95% CI

P-value

0.513

0.053–4.955

0.564

proBNP

1.001

1.000–1.002

0.066

6 MWT

1.071

0.918–1.250

0.381

Sat0

0.990

0.979–1.001

0.064

Sat1

1.096

0.948–1.268

0.217

Sat2

1.035

0.896–1.196

0.638

Sat decrease

0.759

0.560–1.029

0.076

HR0

0.960

0.885–1.040

0.317

HR1

0.939

0.885–0.996

0.036

HR2

0.730

0.406–1.312

0.293

HR increase

0.949

0.894–1.006

0.080

At diagnosis WHO-FC

At last evalution
WHO-FC
I-II

20

-

1

III-IV

9

3 (33.3)

9.393

0.975–55.492

0.049

proBNP

1.001

1.000–1.001

0.004

6 MWT

0.983

0.969–0.998

0.025

Sat0

1.039

0.902–1.196

0.596

Sat1

1.027

0.975–1.083

0.315

Sat2

0.991

0.916–1.072

0.822

Sat decrease

0.955

0.876–1.042

0.301

HR0

1.033

0.934–1.143

0.526

HR1

0.991

0.941–1.043

0.724

HR2

0.983

0.914–1.058

0.650

HR increase

0.976

0.912–1.044

0.478

WHO-FC: World Health Organization-Functional Class, proBNP: brain natriuretic peptide,
SAT0: baseline O2 saturation before the test, SAT1: O2 saturation at the end of the test, SAT2: O2
saturation 5 min after the test, HR0: baseline heart rate before the test, HR1: heart rate at the end
of the test, HR2: heart rate 5 min after the test.

Recovery of heart rate at the first minute has been shown
to be a predictor factor in adults with PAH. Ramos et al.
have reported that adult patients whose recovery of heart
rate at the first minute > 18 pulses have better hemodynamic
outcomes, NYHA scores and 6MWT distances. Because
the autonomic nervous system dysfunction in patients with
PAH increases morbidity and mortality [13,15]. In Douwes
et al.’s study with 47 pediatric patients with PAH (15 with
PAH-CHD and 32 with IPAH), recovery of heart rate at the
fifth minute and increase in heart rate had no prognostic

value in pediatric patients with PAH [16]. In our study, pretreatment HR1 was associated with survival, and similar to
Douwes et al., pre- or post-treatment heart rate increase
was shown not to affect survival [16]. Although our study
showed that post-treatment HR1 did not affect survival,
having a higher HR1 after the treatment may indicate a
better response to exercise due to the partial improvement
of post-treatment cardiac autonomic functions.
As in the study of Douwes et al., our study also
demonstrated that the post-treatment saturation at the
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Figure 1. ROC analysis of cut-off value for 6MWT.

Figure 2. Cumulative survival of 6MWT for 315 m.

end of the exercise (Sat1) had a negative correlation with
WHO-FC, the post-treatment desaturation rate had a
positive correlation with FC and neither of these two had
any correlation with proBNP [16]. Even though Sat1 and
desaturation rate did not affect survival, their correlation
with post-treatment FC, which is a factor for survival, may
provide hints on prognosis.
Zuk et al. reported 6MWT was negatively correlated
with the maximum heart rate, but there was no correlation
between these two parameters in our study [19]. The
presence of a shunt in pediatric patients with PAH was
associated with shorter 6MWT distance, lower saturation
at rest and higher desaturation rate after effort [19].
Lammers et al. [22] and Douwes et al. [16] have also
reported similar results. Impaired exercising capacity and
decreased saturation in PAH patients without a shunt are
thought to be associated with decreased cardiac output due
to right ventricle impairment and ventilation-perfusion
mismatch due to gas diffusion disorder at the pulmonary
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vascular bed [23]. In patients with PAH having a shunt, the
cardiac index during exercise increases or is maintained at
the same level depending on the increase in the right-toleft shunt and this results in a further decline in saturation
in these patients. Since there were only 2 patients with
IPAH in our study, the comparison of these 2 groups
couldn’t be done.
Although Douwes et al. found that the decrease in
saturation during 6MWT was associated with poor
survival in patients having a shunt, our study showed no
association [16]. Zuk et al. also reported the presence of
higher desaturation during effort in patients having a shunt
but did not evaluate its association with survival [19]. The
results may have differed because, unlike other studies,
a large majority of the patients in our study consisted of
patients with PAH secondary to congenital heart disease.
In patients with Eisenmenger syndrome, decreased right
ventricle workload due to increased right-to-left shunt
during exercise, presence of an escape for compensation
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and maintaining the cardiac index as a result of these have
beneficial effects, but our study did not show any effect of
the desaturation rate on their survival in these patients.
Our study showed that patients who were FC III-IV
had shorter 6MWT distance and higher proBNP levels
both before and after the treatment compared to those
who were FC I-II. These results are similar to Zuk et al.
study [19]. However, Zuk et al. reported resting and peak
HR were significantly higher in patients who were FC IIIIV, but they found no difference in resting saturation and
desaturation [19]. Our study did not show any difference
between these two groups in terms of heart rate. The pretreatment heart rate increase was significantly higher in
patients who were FC I-II and the post-treatment Sat2
significantly lower in those who were FC III-IV.
We didn’t find any prognostic effect of mean PAP on
survival similarly to the literature. [24]. Also, there was an
increase in mean PAP after PAH-specific treatment in our
study. It is well known that PAH is a progressive disease.
Therefore, an increase in mean PAP is an expected result in
patients with PAH, especially in IPAH. However, the effect
of PAH-specific treatments on mean PAP remains unclear
[25–27].
The limitations of our study include; a small number of
patients and the inability to make a comparison between

IPAH and secondary PAH because the majority of our
participants consisted of patients with PAH secondary to
congenital heart disease. Additionally, the heart rate at the
first minute which has been shown to have a prognostic
value in adult patients with PAH was not evaluated [13,15].
In conclusion, this study showed that post-treatment
6MWT, FC and proBNP had prognostic value in pediatric
patients with PAH. The decrease in saturation and
increase in heart rate were not found to have a prognostic
value. Pre-treatment HR1 was associated with survival.
Identification of these prognostic factors at the beginning
and throughout the treatment may be a guide for detecting
the severity of the disease and follow-up.
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